Meet Korean Pharma companies in Basel (EN)

Participation is free, however registration is required before March 10th, 2023.
In case of any questions, please contact events@baselarea.swiss

Daewoong Pharmaceutical
Daewoong established in 1945 has the largest prescription drug sales in the South Korean market and commercializes 10 blockbuster products. Their core competencies are drug development and expanded regional and global collaborations with international partners. They’ve invested approximately 15% of their sales in R&D. Especially, two NCEs, a novel P-CAB class for the treatment of GERD and Gastritis, “Fexuprazan” and, “Enavogliflozin” a novel SGLT2 inhibitor for T2DM were approved in Korea last year. Also, of the 5 different R&D fields within DW, iN Therapeutics(iNT), a research-based biotech, focusing on innovation to develop first-in-class drugs of ion channels for neurological disorders was the most promising one, which resulted in spinning off from DW and establishing stand-a-lone cooperation in 2020. With success in preclinical data, a phase 1 SAD study of iN1011-N17 expected to be a new analgesic is being conducted in Australia.

Ildong Pharmaceutical
A fully integrated pharmaceutical company founded in 1941. In the past few years, they have maintained an industry-leading R&D investment level (15-20% of sales) which has resulted in over 25 innovative R&D assets including five clinical programs. The pipelines cover multiple therapeutic areas including metabolic, GI, ophthalmology, CNS, and oncology.

Yuhan Corporation
This top-selling pharmaceutical company was founded in 1926. Their sales revenue is $1.5B. In the past several years, Yuhan has signed licensing deals with Gilead, Janssen, Boehringer Ingelheim and other global pharmaceutical companies with a combined deal size exceeding $3.5B. The company is looking for collaboration opportunities to jointly develop advanced life science ecosystems with other global pharmaceutical players around the world.